Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aquila Resources Inc. stock logo
AQA
Aquila Resources
C$0.08
C$0.06
C$0.14
C$28.86MN/A120,403 shs68,000 shs
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
$1.80
$1.38
$3.66
$90.92M1.2656,165 shs10,300 shs
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
$7.21
+1.8%
$7.97
$5.99
$13.50
$356.90M0.36167,832 shs67,018 shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.08
+9.7%
$0.12
$0.07
$1.42
$3.05M1.973.34 million shs1.68 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aquila Resources Inc. stock logo
AQA
Aquila Resources
0.00%0.00%0.00%0.00%0.00%
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
0.00%0.00%0.00%0.00%+10.81%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-0.28%+0.28%-7.21%-6.72%-21.33%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+0.52%-7.50%-43.61%-52.62%+7,769,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/AN/AN/AN/AN/AN/AN/AN/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
N/AN/AN/AN/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
1.3972 of 5 stars
3.50.00.00.02.51.70.6
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/AN/AN/AN/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
N/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
3.00
Buy$21.00191.26% Upside
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/AN/AN/A15.00C($0.06) per shareN/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
$121.04M0.00N/A28.83$1.40 per share0.00
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/A$4.58 per shareN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.21N/AN/A$0.12 per share0.70

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/A-C$0.02N/AN/AN/AN/AN/AN/AN/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
-$580K-$0.01N/AN/AN/A-1.39%-5.84%-4.46%N/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$76.41M-$1.92N/AN/AN/AN/A-42.20%-36.66%5/9/2024 (Estimated)
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.21N/A-65.46%-150.14%-53.48%5/28/2024 (Estimated)

Latest ATY, TSTR, AQA, NBY, and AURA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
-$0.39-$0.50-$0.11-$0.50N/AN/A
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/AN/AN/AN/AN/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
N/AN/AN/AN/AN/A
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/A
0.62
0.61
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
0.04
3.69
3.69
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
N/A
18.76
18.76
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
8.66%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
96.75%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
23.25%

Insider Ownership

CompanyInsider Ownership
Aquila Resources Inc. stock logo
AQA
Aquila Resources
N/A
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
11.98%
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
5.90%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
1.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aquila Resources Inc. stock logo
AQA
Aquila Resources
11339.54 millionN/ANot Optionable
AcuityAds Holdings Inc. stock logo
ATY
AcuityAds
18756.83 million50.02 millionNot Optionable
Aura Biosciences, Inc. stock logo
AURA
Aura Biosciences
8849.50 million46.58 millionNot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable

ATY, TSTR, AQA, NBY, and AURA Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aquila Resources logo

Aquila Resources

TSE:AQA
Aquila Resources Inc., together with its subsidiaries, engages in the acquisition, exploration, and development of mineral properties in the United States and Canada. The company primarily explores for zinc, gold, copper, lead, silver, and nickel deposits. Its flagship property is the 100% owned Back Forty project, a development stage volcanogenic massive sulfide deposit located in Menominee County, Michigan. Aquila Resources Inc. is headquartered in Toronto, Canada.
AcuityAds logo

AcuityAds

NYSE:ATY
AcuityAds Holdings, Inc. engages in the provision of digital advertising solutions. It operates through the following geographical segments: Unites States, Canada, and Europe and Other. The company was founded by Tal Hayek, Nathan Mekuz, Rachel Kapcan, and Joe Ontman on October 9, 2009 and is headquartered in Toronto, Canada.
Aura Biosciences logo

Aura Biosciences

NASDAQ:AURA
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.